Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
31.98
-0.09 (-0.28%)
Jul 3, 2025, 4:00 PM - Market closed
Supernus Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 668 | 661.82 | 607.52 | 667.24 | 579.78 | 520.4 | Upgrade
| |
Revenue Growth (YoY) | 11.82% | 8.94% | -8.95% | 15.09% | 11.41% | 32.50% | Upgrade
|
Cost of Revenue | 77.36 | 77.91 | 83.78 | 87.22 | 75.06 | 52.46 | Upgrade
|
Gross Profit | 590.64 | 583.91 | 523.74 | 580.02 | 504.71 | 467.94 | Upgrade
|
Selling, General & Admin | 343.61 | 335.78 | 336.36 | 377.22 | 304.76 | 200.68 | Upgrade
|
Research & Development | 110.79 | 108.8 | 91.59 | 74.55 | 90.47 | 75.96 | Upgrade
|
Operating Expenses | 532.03 | 522.56 | 510.34 | 534.4 | 425.22 | 292.34 | Upgrade
|
Operating Income | 58.61 | 61.36 | 13.4 | 45.61 | 79.5 | 175.6 | Upgrade
|
Interest Expense | - | - | -2.42 | -7.07 | -23.42 | -23.75 | Upgrade
|
Interest & Investment Income | 1.03 | - | - | - | 10.22 | 14.35 | Upgrade
|
Other Non Operating Income (Expenses) | 16.2 | 16.2 | 10.45 | 21.68 | - | - | Upgrade
|
EBT Excluding Unusual Items | 75.83 | 77.55 | 21.44 | 60.22 | 66.3 | 166.2 | Upgrade
|
Gain (Loss) on Sale of Investments | 0.01 | 0.01 | - | 0.01 | 0.35 | 4.35 | Upgrade
|
Asset Writedown | - | - | -20.19 | - | - | - | Upgrade
|
Other Unusual Items | -2.65 | 6.11 | 1.52 | 0.51 | 6.53 | -1.9 | Upgrade
|
Pretax Income | 91.8 | 97.87 | 2.77 | 60.74 | 73.18 | 168.65 | Upgrade
|
Income Tax Expense | 29.88 | 24.01 | 1.45 | 0.03 | 19.75 | 41.7 | Upgrade
|
Net Income | 61.91 | 73.87 | 1.32 | 60.71 | 53.42 | 126.95 | Upgrade
|
Net Income to Common | 61.91 | 73.87 | 1.32 | 60.71 | 53.42 | 126.95 | Upgrade
|
Net Income Growth | - | 5512.84% | -97.83% | 13.64% | -57.92% | 12.29% | Upgrade
|
Shares Outstanding (Basic) | 55 | 55 | 55 | 54 | 53 | 53 | Upgrade
|
Shares Outstanding (Diluted) | 56 | 56 | 56 | 62 | 54 | 54 | Upgrade
|
Shares Change (YoY) | 2.52% | 0.81% | -10.01% | 13.47% | 1.24% | -0.24% | Upgrade
|
EPS (Basic) | 1.12 | 1.34 | 0.02 | 1.13 | 1.01 | 2.41 | Upgrade
|
EPS (Diluted) | 1.11 | 1.32 | 0.02 | 1.04 | 0.98 | 2.36 | Upgrade
|
EPS Growth | - | 6500.00% | -98.08% | 6.32% | -58.48% | 12.38% | Upgrade
|
Free Cash Flow | 163.35 | 171.23 | 110.53 | 116.41 | 125.08 | 134.71 | Upgrade
|
Free Cash Flow Per Share | 2.92 | 3.06 | 1.99 | 1.89 | 2.30 | 2.51 | Upgrade
|
Gross Margin | 88.42% | 88.23% | 86.21% | 86.93% | 87.05% | 89.92% | Upgrade
|
Operating Margin | 8.77% | 9.27% | 2.21% | 6.84% | 13.71% | 33.74% | Upgrade
|
Profit Margin | 9.27% | 11.16% | 0.22% | 9.10% | 9.21% | 24.39% | Upgrade
|
Free Cash Flow Margin | 24.45% | 25.87% | 18.19% | 17.45% | 21.57% | 25.89% | Upgrade
|
EBITDA | 138.66 | 141.77 | 98.26 | 131.16 | 112.09 | 193.74 | Upgrade
|
EBITDA Margin | 20.76% | 21.42% | 16.17% | 19.66% | 19.33% | 37.23% | Upgrade
|
D&A For EBITDA | 80.05 | 80.41 | 84.86 | 85.54 | 32.6 | 18.14 | Upgrade
|
EBIT | 58.61 | 61.36 | 13.4 | 45.61 | 79.5 | 175.6 | Upgrade
|
EBIT Margin | 8.77% | 9.27% | 2.21% | 6.84% | 13.71% | 33.74% | Upgrade
|
Effective Tax Rate | 32.55% | 24.53% | 52.47% | 0.05% | 26.99% | 24.73% | Upgrade
|
Revenue as Reported | 668 | 661.82 | 607.52 | 667.24 | 579.78 | 520.4 | Upgrade
|
Updated May 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.